MDA Awards Grant to HNF for Groundbreaking Digital Wearable Study on CMT!

by | Feb 3, 2025 | 0 comments

Exciting news for the Charcot-Marie-Tooth (CMT) community! The Hereditary Neuropathy Foundation (HNF) has been awarded an Advocacy Collaboration Grant from the Muscular Dystrophy Association (MDA) to further its groundbreaking work in CMT research. This funding will drive critical advancements in understanding how CMT affects mobility and quality of life—and we need YOU to be part of it!

As part of this initiative, HNF has partnered with BioSensics™ to conduct a pioneering wearable technology study designed to remotely monitor daily activities and functions of people living with CMT in real-world settings. This study utilizes FDA-registered wearable devices like PAMSys™, which continuously track movement, providing invaluable data that can help researchers and clinicians better understand CMT’s impact.

Why does this matter?

Shaping the Future of CMT Treatment – Real-world data is key to improving therapies and clinical trials.

Improving Patient Advocacy & Research – Your participation helps drive policy changes and better support for the CMT community.

Easy & Non-Invasive – The wearable device collects data seamlessly, requiring little effort from you!

Be a Part of This Game-Changing Study at the CMT Summit!

We are actively seeking participants aged 8-70 to join this important study at the upcoming HNF Clinical Trial Readiness Summit, happening April 24-26 in Nashville, TN. This is your chance to contribute to research, meet leading experts in the field, and connect with others in the CMT community.

Don’t Miss Out – Sign Up Now!

Be a driving force in the future of CMT treatments and research. Register for the HNF Summit and sign up for the wearable tech study today.

Have questions about the summit or wearable study?

Join us on zoom Wednesday, Feb. 27, 2025 anytime between 3:00pm – 4:00pm ET

Learn more on this topic

Related Blog Posts

A New Mouse Model for Charcot-Marie-Tooth (CMT2)

We were recently informed that The Jackson Laboratory (JAX, a nonprofit biomedical research institution headquartered in Bar Harbor, Maine) had taken delivery and will be distributing a newly generated CMT-related mouse model. The new model expresses mutant mitofusin 2, a mitochondrial membrane protein involved in mitochondrial fusion and regulation of vascular smooth muscle cell proliferation.

Hot Off the Press – Potential Treatment for CMT1A

Two recent publications from Pharnext describe a novel synergistic combination of 3 drugs (baclofen, naltrexone and sorbitol) and its effect on CMT1A both in the lab and in a phase II clinical trial. These 3 drugs already approved but for unrelated conditions, are combined at new optimal lower doses and under a new formulation. This novel potential therapeutic is called PXT-3003.

Support CMT Therapeutic Alliance

HNF has entered into a joint venture – the CMT Therapeutic Alliance – with a unique non profit organization (BioPontis Alliance for Rare Diseases) that brings professional drug discovery capabilities to translate our research results into potential treatments.

Scientific Advisory Board Meeting

Scientific Advisory Board Meeting

On the 7th of November we convened our scientific advisory board meeting at the HNF offices in NY. We have written a detailed review that has been published and captures all of the discussion and make this freely available to the scientific community.

Breaking News: First Therapeutic Gene Therapy to Treat an Inherited Neuropathy is Approved for Clinical Trial!

The first disease community to receive a therapeutic gene to the spinal cord for an ultra rare inherited neuropathy is Giant Axonal Neuropathy (GAN). Congratulations to Hannah’s Hope Fund (HHF), a 501(c)3 public charity, which has driven this collaborative research in less than six years. Six million dollars has been raised to date to fund pre-clinical and clinical research on this rare disease.

Pharnext Announces Pleotherapy Proof of Concept in Charcot-Marie-Tooth Disease Type 1A

Pharnext Announces Pleotherapy Proof of Concept in Charcot-Marie-Tooth Disease Type 1A

PARIS, December 18th, 2014 – Pharnext SAS today announced the proof of concept of its pleotherapy research and development approach based on a proprietary network pharmacology platform that identifies synergic combinations of drugs already approved for other diseases. Indeed, Pharnext’s lead pleodrug, PXT-3003, has shown positive results both in preclinical and Phase 2 clinical studies published today in the Orphanet Journal of Rare Diseases.

Join the conversation

Leave a Comment

0 Comments

Submit a Comment

Your email address will not be published. Required fields are marked *

Newsletter

Join for notifications on events, campaigns, & news